Calcium/calmodulin-dependent protein kinase II (CaMKII) is a serine/threonine kinase that plays a critical role in synaptic plasticity, memory formation, and neuronal survival. In the brain, CaMKII is highly enriched in postsynaptic densities and functions as a molecular decoder of calcium signals, translating transient calcium influx into durable changes in synaptic strength. Dysregulation of CaMKII signaling has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders, making it a promising therapeutic target[1].
The CaMKII holoenzyme consists of 12 subunits arranged in two stacked hexameric rings, with each subunit containing an N-terminal catalytic domain, a regulatory segment, and a C-terminal association domain. The two predominant isoforms in the brain are CaMKIIα (predominantly neuronal) and CaMKIIβ (expressed in neurons and glia). Autophosphorylation at Thr286 renders CaMKIIα constitutively active, enabling calcium-independent kinase activity that underlies long-term potentiation (LTP) and memory consolidation[2].
Postmortem studies have consistently demonstrated reduced CaMKII activity in AD brain tissue[3]. This reduction correlates with cognitive decline and neurofibrillary tangle burden. The mechanism involves multiple pathways:
CaMKII can phosphorylate tau protein at multiple sites, including Ser262, which regulates tau's affinity for microtubules[6]. In AD, dysregulated CaMKII activity contributes to abnormal tau phosphorylation and aggregation. Notably, CaMKII-mediated tau phosphorylation is bidirectional with GSK3β, creating a feed-forward loop that accelerates pathology[7].
The interaction between CaMKII and tau follows this cascade:
CaMKII is essential for LTP, the cellular correlate of learning and memory. In AD models, Aβ-induced synaptic dysfunction involves CaMKII inhibition:
A key link between CaMKII and PD is the phosphorylation of alpha-synuclein (α-syn) at Ser129[12]. While phosphorylation at this site is traditionally viewed as a pathological marker, it may represent a protective mechanism that reduces α-syn aggregation. CaMKII is one of several kinases capable of phosphorylating α-syn at Ser129, and this modification:
CaMKII signaling intersects with mitochondrial dysfunction in PD[13]. Pathogenic LRRK2 mutations enhance CaMKII activation, leading to:
The CaMKII-mitochondria axis provides a mechanistic link between synaptic dysfunction and energy failure in PD.
Activated CaMKII phosphorylates numerous substrates involved in neurodegeneration:
| Substrate | Site | Function in Neurodegeneration |
|---|---|---|
| CREB | Ser133 | Memory transcription, altered in AD |
| NMDA Receptor | Multiple | Synaptic plasticity, excitotoxicity |
| AMPA Receptor | Ser831 | Synaptic strength |
| Tau | Ser262, Thr205 | Microtubule binding, aggregation |
| alpha-Syn | Ser129 | Aggregation, clearance |
| p53 | Ser15 | Apoptosis regulation |
| Mitochondrial proteins | Multiple | Energy metabolism |
Recent studies reveal isoform-specific alterations in AD brain[14]:
CaMKII interacts extensively with other signaling pathways[15]:
Pharmacological inhibition of CaMKII has shown neuroprotective effects in multiple models[16]:
CaMKII activity in cerebrospinal fluid (CSF) shows promise as a biomarker for synaptic dysfunction in AD[17:1]:
Transgenic and knockout models have illuminated CaMKII's role in neurodegeneration[18]:
CaMKII represents a central node in the molecular network governing synaptic plasticity and neuronal survival. Its dysregulation in AD and PD creates a cascade of deleterious effects on tau pathology, alpha-synuclein phosphorylation, mitochondrial function, and synaptic plasticity. Targeting CaMKII offers a multi-modal therapeutic approach, though careful attention to isoform specificity and therapeutic window is essential. The development of biomarker assays for CaMKII activity further positions this kinase as both a therapeutic target and a diagnostic tool in neurodegeneration.
Yamauchi T, et al. CaMKII as therapeutic target in neurodegenerative diseases. Pharmacol Rev. 2022. ↩︎
Sheng M, et al. CREB phosphorylation via CaMKII in memory formation. Nature. 2000. ↩︎
Cheng H, et al. Decreased Ca2+/calmodulin-dependent protein kinase II activity in Alzheimer's disease. Neurosci Lett. 2000. ↩︎
Reese LC, et al. Amyloid beta oligomers inhibit CaMKII autophosphorylation. J Biol Chem. 2010. ↩︎
Wang Y, et al. CaMKII mediates oxidative stress-induced neuronal death. Free Radic Biol Med. 2023. ↩︎
Takashima A, et al. Phosphorylation of tau protein by Ca2+/calmodulin-dependent protein kinase II. J Biol Chem. 2003. ↩︎
Liu R, et al. Interaction between CaMKII and GSK3beta in tau pathology. Acta Neuropathol Commun. 2023. ↩︎
Strack S, et al. CaMKII regulates NMDA receptor function and phosphorylation. J Neurosci. 2001. ↩︎
Derksen M, et al. CaMKII regulates AMPA receptor trafficking in synaptic plasticity. Neuron. 2002. ↩︎
Bosch M, et al. CaMKII in dendritic spine morphology and plasticity. Nat Rev Neurosci. 2014. ↩︎
Kim S, et al. CaMKII dysfunction impairs hippocampal theta oscillations. J Neurosci. 2024. ↩︎
Okochi M, et al. Phosphorylation of alpha-synuclein at Ser129 by CaMKII. J Biol Chem. 2008. ↩︎
Liu J, et al. CaMKII signaling in mitochondrial dysfunction in neurodegeneration. Cell Death Discov. 2021. ↩︎
Maire J, et al. Isoform-specific CaMKII alterations in AD brain. Acta Neuropathol. 2023. ↩︎
Li M, et al. Cross-talk between CaMKII and p38 MAPK in neurodegeneration. Cell Mol Neurobiol. 2023. ↩︎
Zhang Y, et al. CaMKII inhibition provides neuroprotection in various models. Neurobiol Dis. 2024. ↩︎
Chen X, et al. CaMKII activity as biomarker for synaptic dysfunction in AD. Brain. 2024. ↩︎ ↩︎
Chen L, et al. CaMKII transgenic and knockout models in neurodegeneration. Prog Neuropsychopharmacol Biol Psychiatry. 2023. ↩︎